EXPLORE CONNECTIONS

Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.

Follow the relationships that help you find your next source.

Connections are not prepared for this record yet, or its source metadata has changed. The original record remains available while background snapshots are rebuilt.